AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,906.00p
   
  • Change Today:
    232.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,667.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.67m
  • Volume: 1,782,115
  • Market Cap: £169,116m
  • RiskGrade: 123

Latest ShareCast News

AstraZeneca reports positive results from autoimmune treatment trial

By Josh White

Date: Thursday 24 Jul 2025

(Sharecast News) - AstraZeneca announced on Thursday that its investigational treatment 'gefurulimab' achieved statistically significant and clinically meaningful results in a phase three trial for generalised myasthenia gravis (gMG), a rare autoimmune neuromuscular disorder.

AstraZeneca ShareCast News

AstraZeneca to invest $50bn in US manufacturing ... 22-Jul-2025 ShareCast
London close: Stocks fall after rise in UK consu... 16-Jul-2025 ShareCast
AstraZeneca drug fails to meet main goal in late... 16-Jul-2025 ShareCast
London close: Stocks rise despite renewed trade ... 14-Jul-2025 ShareCast
Berenberg raises target price on AstraZeneca 09-Jul-2025 ShareCast

AstraZeneca Regulatory News

Gefurulimab nanobody met Phase III endpoints 24-Jul-2025 07:00 RNS
AstraZeneca plans to invest $50bn in the US 22-Jul-2025 07:00 RNS
Update on anselamimab in AL amyloidosis 16-Jul-2025 07:00 RNS
Baxdrostat met primary endpt in BaxHTN PhIII trial 14-Jul-2025 07:00 RNS
Imfinzi approved in the EU for bladder cancer 04-Jul-2025 07:00 RNS

AstraZeneca Newspaper Links

AstraZeneca to invest $50bn in United States 22-Jul-2025 Times
Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail
Some reasons why Pfizer won’t bid for AstraZenec... 19-Nov-2014 Guardian

AstraZeneca Tips & Analysis

Questor :AstraZeneca 29-Apr-2014 Telegraph
Questor : AstraZeneca 24-Jan-2014 Telegraph
Questor:AstraZeneca 22-Dec-2011 Telegraph
Investment Column:AstraZeneca 28-Oct-2011 The Independent
Investment Column: AstraZeneca 23-Jun-2011 The Independent

AstraZeneca News Wires

MedImmune Announces Zook as President 13-Nov-2008 PR Newswire
Survey Shows Lung Cancer Patients Blamed for The... 12-Nov-2008 PR Newswire
CRESTOR Demonstrates Dramatic CV Risk Reduction ... 09-Nov-2008 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,906.00p
Change Today 232.00p
% Change 2.17 %
52 Week High 13,276.00p
52 Week Low 9,667.00p
Volume 1,782,115
Shares Issued 1,550.67m
Market Cap £169,116m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.98% below the market average93.98% below the market average93.98% below the market average93.98% below the market average93.98% below the market average
82.61% below the sector average82.61% below the sector average82.61% below the sector average82.61% below the sector average82.61% below the sector average
Price Trend
21% below the market average21% below the market average21% below the market average21% below the market average21% below the market average
28.89% above the sector average28.89% above the sector average28.89% above the sector average28.89% above the sector average28.89% above the sector average
Income
63.71% below the market average63.71% below the market average63.71% below the market average63.71% below the market average63.71% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
87.44% above the market average87.44% above the market average87.44% above the market average87.44% above the market average87.44% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 14
Neutral 5
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 24-Jul-2025

Time Volume / Share Price
16:23 0 @ 10,916.00p
15:54 0 @ 10,928.00p
15:10 0 @ 10,954.00p
15:10 0 @ 10,954.00p
15:10 0 @ 10,954.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page